We are a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health.

Our RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Our toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology.

Our diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency, and Huntington’s disease, as well as a preclinical program in obesity. Driven by the calling to “Reimagine Possible,” we are leading the charge toward a world in which human potential is no longer hindered by the burdens of disease.

In The Spotlight

Wave Life Sciences initial public offering with Nasdaq

Press Releases

Feb 28, 2024

Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024

Feb 27, 2024

Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy

View all news

Corporate Presentation

Download
Corporate Presentation

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Learn More